Results 91 to 100 of about 21,386 (303)

Castleman Disease: A Multicenter Case Series from Turkey

Turkish Journal of Hematology, 2022
Objective: Castleman disease (CD) is a rare disease also known as angiofollicular lymph node hyperplasia. The two main histological subtypes are the hyaline vascular and plasma cell variants.
Eren Gündüz, Hakkı Onur Kırkızlar, Elif Gülsüm Ümit, Sedanur Karaman Gülsaran, Vildan Özkocaman, Fahir Özkalemkaş, Ömer Candar, Tugrul Elverdi, Selin Küçükyurt, Semra Paydaş, Özcan Çeneli, Sema Karakuş, Senem Maral, Ömer Ekinci, Yıldız İpek, Cem Kis, Zeynep Tuğba Güven, Aydan Akdeniz, Tiraje Celkan, Ayşe Hilal Eroğlu Küçükdiler, Gülsüm Akgün Çağlıyan, Ceyda Özçelik Şengöz, Ayşe Karataş, Tuba Bulduk, Alper Özcan, Fatma Burcu Belen Apak, Aylin Canbolat, İbrahim Kartal, Hale Ören, Ersin Töret, Gül Nihal Özdemir, Şule Mine Bakanay Öztürk   +31 more
doaj   +1 more source

Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor induced growth arrest and apoptosis through NF-κB activation [PDF]

, 2013
Kaposi's sarcoma-associated herpesvirus (KSHV) has been linked to the development of Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease (MCD). We have characterized the role of KSHV-encoded viral FLICE inhibitory protein K13
Ahmad, B. Tolani, Ballon, Benhamou, Bower, Bren, C. Graham, Chang, Chaudhary, Chugh, Delmore, Dong, Du, Dupin, Dupin, Eeva, Eeva, Field, Gerondakis, Guasparri, H. Matta, H. Yi, Hassman, Herzog, Lee, Liu, Madureira, Matta, Matta, Matta, Matta, Mineva, Nador, Niiro, P. M. Chaudhary, Parravicini, Punj, Schauer, Soulier, Sun, Sun, Sun, Thome, Vrzalikova, Waterston, Wu, Wu, Wu, Y. Suo, Y. Yang, Yang, Yang, Young, Zhao   +53 more
core   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Volume 78, Issue 1, Page 12-25, January 2026.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Castle man disease: a case report and review of the literature

The Pan African Medical Journal, 2014
The Castleman disease (CD) is a rare disease of unknown etiology, characterized histologically by angiofollicular lymphoid hyperplasia. It comes in two forms, unicentric and multicentric.
Mounir Kettani, Nabil Touiheme, Hicham Attifi, Mounir Hmidi, Ali Boukhari, Mohamed Zalagh, Abdelhamid Messary   +6 more
doaj   +1 more source

Retroperitoneal Castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity [PDF]

, 2014
BACKGROUND: Castleman’s disease is a rare and poorly understood disease entity that may resemble more common conditions and represents a clinical challenge to the treating surgeon.
Adriana Sanchez, Austin D Williams, Blake D Babcock, Jun Hou, Mark E Hysell, Michael S Weingarten, Mohammad F Shaikh, Rene Rubin, Wilbur B Bowne   +8 more
core   +1 more source

HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis. [PDF]

, 2020
Multicentric Castleman disease is a rare polyclonal lymphoproliferative disorder mainly associated with two renal manifestations: thrombotic microangiopathy and amyloidosis.
Duss, F.R., Halfon, M., Nunes, M.B., Rotman, S.   +3 more
core   +1 more source

Increased mTOR activation in idiopathic multicentric Castleman disease.

Blood, 2020
Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly-understood hematologic disorder characterized by lymphadenopathy, systemic inflammation, cytopenias, and life-threatening multi-organ dysfunction.
Daniel J. Arenas, Katherine Floess, D. Kobrin, R. Pai, M. B. Srkalovic, M. Tamakloe, R. Rasheed, Jasira Ziglar, J. Khor, Sophia A T Parente, S. Pierson, D. Martinez, G. Wertheim, T. Kambayashi, J. Baur, D. Teachey, D. Fajgenbaum   +16 more
semanticscholar   +1 more source

Multicentric Castleman Disease

Health and Ecology Issues, 2019
The article is devoted to the discussion of the specific features of Castleman disease, a clinical case of its multicentric variant, and analyzes the patient`s case report, the clinical data and results of the laboratory and instrumental methods of research.
E. N. Shcherbakova, E. G. Malayeva, E. V. Ostapova   +2 more
openaire   +2 more sources

Siltuximab for Multicentric Castleman Disease—Letter [PDF]

Clinical Cancer Research, 2015
We read with great interest the article by Deisseroth and colleagues ([1][1]) focusing on the recent global approval of the monoclonal IL6 antibody siltuximab for the treatment of patients with HHV-8-, HIV-negative multicentric Castleman disease (MCD).
Raphael, Teipel, Rainer, Ordemann, Ulrike, Proske, Frank, Dietrich, Marika, Mende, Gerhard, Ehninger, Frank, Kroschinsky, Uwe, Platzbecker   +7 more
openaire   +2 more sources

Toward Anti‐Herpesviral PROTACs: Assessing the Challenges for Targeted Protein Degradation on the Example of Kaposi's Sarcoma‐Associated Herpesvirus Latency‐Associated Nuclear Antigen

ChemMedChem, Volume 21, Issue 1, January 2026.
It is attempted to employ proteolysis‐targeting chimeras‐based targeted protein degradation to the viral protein “Latency‐associated Nuclear Antigen” from Kaposi's sarcoma‐associated herpesvirus. While ternary complex formation is detected via native mass spectrometry, protein degradation is not observed, presumably due to insufficient permeability ...
Aylin Berwanger, Saskia Catherina Stein, Sarah Brandner, Andreas Martin Kany, Sebastian Heinz, Brigitta Loretz, Claus‐Michael Lehr, Anna Katharina Herta Hirsch, Frederik Lermyte, Thomas Friedrich Schulz, Martin Empting   +10 more
wiley   +1 more source